Skip to main content
    R

    Regeneron Pharmaceuticals Inc (REGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $805.02
    -14.07 (-1.72%)

    Market Cap: $82.88B

    Last updated: Oct 27, 2026 at 10:41 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    87%(34/39)
    Avg Surprise
    +14.35%
    Streak
    5 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$16.20
    Range$14.88 - $17.68
    23 analysts
    EPS Revisions
    3
    0
    7d
    3
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$13.21+22.7%
    60d ago$16.00+1.3%
    30d ago$15.95+1.6%
    7d ago$16.06+0.8%
    Current$16.20
    Revenue Consensus
    $4.6B
    Range$4.4B - $4.7B
    21 analysts
    Period ending Dec 31, 2026
    EPS Consensus$23.83
    Range$8.12 - $32.65
    28 analysts
    Revenue Consensus
    $5.7B
    Range$3.1B - $6.5B
    26 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$23.83---
    Sep 26EST
    		-$16.20---
    Jun 26
    Reported Jul 30
    		$12.53$8.00+56.63%Beat-2.8%
    Mar 26
    Reported Apr 29
    		$9.47$8.90+6.40%Beat+15.2%
    Dec 25
    Reported Jan 30
    		$11.44$10.75+6.42%Beat-5.2%
    Sep 25
    Reported Oct 28
    		$11.83$9.64+22.72%Beat-5.1%
    Jun 25
    Reported Aug 1
    		$12.89$8.44+52.73%Beat+11.5%
    Mar 25
    Reported Apr 29
    		$8.22$8.48-3.07%Miss-13.9%
    Dec 24
    Reported Feb 4
    		$12.07$11.19+7.86%Beat+1.8%
    Sep 24
    Reported Oct 31
    		$12.46$11.70+6.50%Beat+7.5%
    Jun 24
    Reported Aug 1
    		$11.56$10.62+8.85%Beat+12.9%
    Mar 24
    Reported May 2
    		$9.55$10.10-5.45%Miss-5.4%
    Dec 23
    Reported Feb 2
    		$11.86$10.75+10.33%Beat-5.6%
    Sep 23
    Reported Nov 2
    		$11.59$10.78+7.51%Beat+4.0%
    Jun 23
    Reported Aug 3
    		$10.24$9.90+3.43%Beat+4.8%
    Mar 23
    Reported May 4
    		$10.09$9.56+5.54%Beat-12.2%
    Dec 22
    Reported Feb 3
    		$12.56$10.01+25.47%Beat-47.0%
    Sep 22
    Reported Nov 3
    		$11.14$9.48+17.51%Beat-27.5%
    Jun 22
    Reported Aug 3
    		$9.77$8.76+11.53%Beat-62.1%
    Mar 22
    Reported May 4
    		$11.49$9.80+17.24%Beat+16.2%
    Dec 21
    Reported Feb 4
    		$23.72$20.30+16.85%Beat+148.9%
    Sep 21
    Reported Nov 4
    		$15.37$9.94+54.63%Beat+83.9%
    Jun 21
    Reported Aug 5
    		$25.80$17.71+45.68%Beat+260.3%
    Mar 21
    Reported May 6
    		$9.89$8.68+13.94%Beat+49.8%
    Dec 20
    Reported Feb 5
    		$9.53$8.29+14.96%Beat+27.1%
    Sep 20
    Reported Nov 5
    		$8.36$6.99+19.60%Beat+25.3%
    Jun 20
    Reported Aug 5
    		$7.16$5.97+19.93%Beat+18.9%
    Mar 20
    Reported May 5
    		$6.60$6.09+8.37%Beat+48.3%
    Dec 19
    Reported Feb 6
    		$7.50$7.17+4.60%Beat+9.6%
    Sep 19
    Reported Nov 5
    		$6.67$6.40+4.22%Beat+13.6%
    Jun 19
    Reported Aug 6
    		$6.02$5.42+11.07%Beat+10.5%
    Mar 19
    Reported May 7
    		$4.45$5.52-19.38%Miss-4.7%
    Dec 18
    Reported Feb 6
    		$6.84$5.60+22.14%Beat+30.8%
    Sep 18
    Reported Nov 6
    		$5.87$5.06+16.01%Beat+47.1%
    Jun 18
    Reported Aug 2
    		$5.45$4.68+16.45%Beat+30.7%
    Mar 18
    Reported May 3
    		$4.67$4.34+7.60%Beat+59.9%
    Dec 17
    Reported Feb 8
    		$5.23$4.57+14.44%Beat+72.0%
    Sep 17
    Reported Nov 8
    		$3.99$3.82+4.45%Beat-
    Jun 17
    Reported Aug 3
    		$4.17$3.18+31.13%Beat-
    Mar 17
    Reported May 4
    		$2.92$3.07-4.89%Miss-
    Dec 16
    Reported Feb 9
    		$3.04$3.05-0.33%Miss-

    Dividends

    Dividend Metrics

    Forward Yield0.47%
    Forward Annual Dividend$3.76
    Payout Ratio8.79%
    FrequencyQuarterly
    Pay MonthsMar, Jun, Aug, Dec

    Key Metrics

    Valuation
    P/E Ratio17.78EV/EBITDA14.31x
    Price/FCF22.01xFCF Yield4.54%
    Profitability
    Profit Margin27.90%Operating Margin33.10%
    ROE14.00%ROIC12.98%
    Financial Health
    Debt/Equity0.06xInterest Coverage94.25x
    Current Ratio3.34xQuick Ratio2.78x
    Trading Statistics
    Beta0.15Avg Volume692.50K
    52-Week High$859.3452-Week Low$590.83

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$790.07
    SMA 20$766.26
    SMA 50$791.33
    SMA 200$734.99
    EMA 10$792.20
    EMA 20$782.69
    EMA 50$772.75
    EMA 200$727.78

    MACD

    Line: 8.17Signal: 0.86Hist: 7.32

    ADX

    ADX: 21.2+DI: 28.8-DI: 14.5

    Aroon & PSAR

    Aroon Up96.0
    Aroon Down44.0
    PSAR$766.44

    Bollinger Bands

    Upper Band$824.51
    Lower Band$708.01
    %B Position1520%(Upper)
    Band Width0.83

    RSI (14-Day)

    Neutral
    58.1

    Momentum Oscillators

    Stoch %K88.2
    Stoch %D89.4
    Williams %R-20.1
    ROC (10d)7.8%
    Momentum58.48
    CCI (20d)110.5
    MFI (14d)68.4

    Volatility Measures

    ATR (14d)$21.33(2.6%)
    StdDev (20d)29.13
    Hist Vol32.0%(Moderate)

    Volume Flow

    VWAP$808.44
    OBV820.4K
    AD Line-47.0M
    CMF (20d)-0.004

    Volume Metrics

    Avg Vol (20d)702.0K
    Vol Ratio0.8x
    VWMA (20d)$765.71

    Pivot Points

    R3$855.26
    R2$840.39
    R1$829.74
    Pivot Point$814.87
    S1$804.22
    S2$789.35
    S3$778.70

    Advanced Oscillators

    TSI9.85
    Ultimate Osc53.2
    KST-9.79

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$4.29B$3.61B$3.88B$3.75B$3.68B$3.03B$3.79B$3.72B$3.55B$3.15B$3.43B$3.36B
    Cost of Revenue$576.50M$669.40M$584.60M$521.60M$530.20M$464.30M$565.40M$491.10M$480.20M$433.80M$517.00M$436.40M
    Gross Profit$3.71B$2.94B$3.30B$3.23B$3.15B$2.56B$3.22B$3.23B$3.07B$2.71B$2.92B$2.93B
    Operating Expenses$2.42B$2.29B$2.42B$2.21B$2.07B$1.97B$2.23B$2.05B$2.00B$1.96B$1.94B$1.82B
    R&D$1.76B$1.65B$1.64B$1.56B$1.43B$1.34B$1.43B$1.33B$1.22B$1.26B$1.21B$1.18B
    SG&A$662.10M$647.70M$775.00M$657.80M$634.20M$633.00M$792.20M$714.40M$758.80M$689.00M$737.70M$640.50M
    Operating Income$1.29B$642.90M$879.90M$1.03B$1.08B$591.70M$990.20M$1.18B$1.07B$751.40M$972.90M$1.11B
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$11.00M$12.90M$12.20M$19.30M$3.60M$8.70M$10.50M$13.80M$14.80M$16.10M$18.30M$17.80M
    Income Before Tax$1.53B$831.20M$1.04B$1.76B$1.52B$905.00M$958.10M$1.49B$1.63B$700.70M$1.15B$1.11B
    Income Tax Expense$230.90M$104.00M$199.10M$303.30M$127.10M$96.30M$40.40M$152.40M$195.80M$-21,300,000$-12,000,000$103.00M
    Net Income$1.30B$727.20M$844.60M$1.46B$1.39B$808.70M$917.70M$1.34B$1.43B$722.00M$1.16B$1.01B
    EBITDA$1.66B$967.30M$1.20B$1.92B$1.66B$1.04B$1.09B$1.63B$1.76B$830.90M$1.28B$1.23B
    EBIT$1.54B$844.10M$1.06B$1.78B$1.52B$913.70M$968.60M$1.51B$1.64B$716.80M$1.17B$1.13B
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    The Drug That Nobody Talks About Enough: Regeneron's Hidden Compounding Machine

    Quality meets catalyst: Two regulatory wins in 5 days. Dupixent's AFRS approval + garetosmab Priority Review. Quality Score 98/100. The business is strengthening while the stock trades near fair value. The honest valuation: At $789...

    Glenn Ford
    •
    2/27/26
    •
    186
    Biotech, BioPharma
    Also mentions:
    SNYAMGNTMDXGILD

    Part 2 of 3: The Night the Organ Monopoly Proved It Was Real

    Tonight's earnings confirmed the thesis: Q4 revenue $160.8M (+32%), FY $605.5M (+37%), 5,139 OCS cases (+38%), 2026 guidance $727M–$757M. TMDX has graduated from speculative disruptor to verified logistics monopoly. The 22-aircraft fleet is the moat...

    Glenn Ford
    •
    2/25/26
    •
    154
    healthcare-innovation, Healthcare Stocks
    Also mentions:
    GILDREGN

    Gilead Sciences (GILD): The Fortress Nobody's Paying Attention To

    Gilead's $14.3B Biktarvy franchise grew 7% YoY in 2025, proving HIV isn't ex-growth. Total revenues hit $29.4B. The base business alone justifies ~$150 fair value. Yeztugo (twice-yearly HIV prevention) expands TAM from diagnosed patients to at-risk populations. FDA approved June 2025. $800M combined...

    Glenn Ford
    •
    2/24/26
    •
    148
    Healthcare Stocks, healthcare-innovation
    Also mentions:
    TMDXREGNJNJ

    Incyte’s Earnings: Strong Growth Amid Market Overlook

    INCY generates $1.17B annual FCF with 93% gross margins and zero leverage, yet trades at 15.6x earnings. Reverse-DCF implies ~0% growth priced in. Quality Score 100/100 with ROIC 25.4%, Piotroski 8/9, interest coverage 702x...

    Glenn Ford
    •
    2/11/26
    •
    154
    Biotech, Healthcare Stocks
    Also mentions:
    NVSLLYREGNGILD

    Government Contracts

    Gov Obligations (TTM)
    -$329.36M
    Gov Obligations / Revenue
    -2.1%
    Obligations YoY
    N/A
    Active Awards
    3
    New Awards (TTM)
    0
    Avg Remaining Term
    13.8 mo

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Regeneron lands $270M in renewed US supply pact for approved Ebola med Inmazeb

    Regeneron Pharmaceuticals has secured a renewed $270 million contract with the U.S. government through BARDA to supply its Ebola antibody cocktail, Inmazeb...

    Fierce Pharma•10/27/26•Bullish

    Rare Disease Genome Editing Market Outlook Signals Expansion To $2.88 Billion Through 2030

    The rare disease genome editing market is projected to expand significantly, from $1.29 billion in 2025 to $2.88 billion by 2030, driven by advancements in gene editing tools, increased funding...

    openPR.com•10/27/26•Bullish

    Second Medical Use Claims Before the UPC: Proving the Therapeutic Purpose

    The Düsseldorf Local Division of the Unified Patent Court recently addressed the challenge of proving infringement for second medical use claims...

    Wolters Kluwer•10/27/26•Neutral

    Kymera Therapeutics (KYMR) Could Be 17% Undervalued Following Its Earnings Preview

    Kymera Therapeutics (KYMR) is expected to post a loss of $1.26 per share with sharply higher revenue for the September 2026 quarter...

    Simply Wall Street•10/26/26•Neutral

    Regeneron Extends BARDA Deal for Ebola Treatment Supply for $270M Through 2031

    Regeneron has extended its 2020 agreement with the Biomedical Advanced Research and Development Authority (BARDA) to supply Inmazeb, a three-drug antibody cocktail for Ebola treatment, through 2031. The deal...

    Contract Pharma•10/26/26•Bullish

    REGN Valuation and Fair Value

    P/E
    17.8x
    Forward P/E
    14.1x
    EV/EBITDA
    14.3x
    P/FCF
    22.0x
    PEG
    1.3x
    P/B
    2.6x
    See GNG's fair value

    REGN Profitability: Margins, ROIC and FCF

    Gross margin
    84.9%
    Operating margin
    33.1%
    Net margin
    27.9%
    ROIC
    13.0%
    ROE
    14.0%
    FCF yield
    4.5%

    REGN Competitors

    CompanyTicker
    Elevance Health IncELV
    Cigna CorpCI
    Sanofi ADRSNY
    Moderna IncMRNA
    HCA Healthcare, Inc.HCA
    Boston Scientific CorpBSX
    GlaxoSmithKline PLC ADRGSK
    Takeda Pharmaceutical Co Ltd ADRTAK

    Sector: Healthcare

    REGN Analyst Ratings

    Consensus
    Buy
    Analysts
    27
    Strong Buy
    4
    Buy
    13
    Hold
    9
    Sell
    0
    Strong Sell
    1

    REGN Bull Case vs Bear Case

    Bull case

    • REGN has a 27.9% net profit margin.
    • REGN beat EPS estimates in 87.5% of its last 8 reported quarters.
    • REGN grew quarterly revenue 16.7% year over year.

    REGN Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    19.5%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $16.20
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    3 up, 2 down

    REGN Dividend

    Forward yield
    0.5%
    Payout ratio
    8.8%
    Pay months
    Mar, Jun, Aug, Dec

    Frequently Asked Questions About REGN

    What is REGN's current dividend yield?

    Regeneron Pharmaceuticals Inc (REGN) has a forward dividend yield of 0.47%.

    Does REGN pay dividends?

    Yes, Regeneron Pharmaceuticals Inc pays dividends with a forward dividend yield of 0.47%.

    What is REGN's P/E ratio?

    Regeneron Pharmaceuticals Inc has a price-to-earnings (P/E) ratio of 17.78.

    What is REGN's market cap?

    Regeneron Pharmaceuticals Inc (REGN) has a market capitalization of $82.88B with a current stock price of $805.02.

    Related stocks

    Sector: Healthcare

    All stocks starting with R

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In